Vnda), a leading biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced positive topline. A detailed overview of vanda pharmaceuticals inc Engages in the development and commercialization of therapies for high unmet medical needs The firm intends to treat schizophrenia, jet lag disorder, atopic. Phase 3 anticipated in h1 2026. Vnda) today announced financial and operational results for the fourth quarter and full year ended december.
Fanapt® showed strong performance with net sales of $29.3 million, up 27% yoy, while hetlioz® and ponvory® sales declined The company reported a net loss of $27.2 million for q2 2025 Key regulatory milestones include bysanti™ nda. With the trial linking tradipitant to reduced nausea and vomiting in wegovy patients, the biotech is.
WATCH
